Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00332579 · ClinicalTrials.gov registry record · Phase 2
Double-Blind Naltrexone in Kleptomania
A Phase 2 study of Kleptomania, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT00332579 is a Phase 2 study of Kleptomania that has completed, run by University of Minnesota. The registered enrollment target is 25 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00332579, a Phase 2 study of Kleptomania, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the proposed study is to evaluate the efficacy and safety of naltrexone in kleptomania.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Naltrexone
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2006-05-01 |
| Est. Completion | 2008-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00332579
The ClinicalTrials.gov registry entry for NCT00332579 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kleptomania appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00332579 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00332579 about?
NCT00332579 is a clinical study titled "Double-Blind Naltrexone in Kleptomania". The goal of the proposed study is to evaluate the efficacy and safety of naltrexone in kleptomania.
What is the current status of trial NCT00332579?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2006-05-01. Estimated completion is 2008-09-01.
What conditions does trial NCT00332579 study?
This clinical trial studies the following conditions: Kleptomania.
What interventions are being tested in trial NCT00332579?
The interventions under investigation include: Placebo (DRUG), Naltrexone (DRUG).
Who is sponsoring clinical trial NCT00332579?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00332579 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.